Paper - WANFANG MED ONLINE

You Position: Home > Paper

Therapeutic effect of replication-competent adenovirus-mediated transfer of interleukin-12 gene on the mouse transplanted gastric cancer in vivo

( views:215, downloads:4 )

Author:: No author available

Journal Title:: WORLD CHINESE JOURNAL OF DIGESTOLOGY

Issue:: 7

DOI:: 10.3969/j.issn.1009-3079.2004.07.003

Key Word:: No keyword available

Abstract：目的:研究携带mIL-12基因的增生型腺病毒对小鼠移植胃癌的治疗效果及其作用机制,探讨胃癌治疗的新思路及途径.方法:以ElB55KDa缺失的增生型腺病毒ONYX-015、带有小鼠IL-12(mIL-12)基因的增生型腺病毒CNHK200-mIL-12以及非增生型腺病毒Ad-mIL-12治疗SGC-790lBALB/C裸鼠及MFC 615小鼠胃癌移植模型,从肿瘤大小及动物生存期等方面评价治疗效果;并检测各治疗组的CD4+和CD8+淋巴细胞水平及NK和CTL细胞的杀伤活性,探讨其免疫学作用机制.结果:实验证实增生型腺病毒(ONYX-015,CNHK200-mIL-12)可以有效地杀伤裸鼠体内的SGC-790l胃癌细胞,但是不足以使其完全消退,仅起到延缓生长的作用.荷瘤615小鼠在注射Ad-mIL-12后部分(3/10)肿瘤消退,余者(7/10)生长明显减慢,肿瘤无破溃,生存期明显延长;CNHK200-mIL-12治疗组部分肿瘤(4/10)停止生长,1wk后开始缩小,10-14 d完全消退,其余小鼠肿瘤(6/10)生长明显减慢,肿瘤无破溃,生存期明显延长.免疫学检测发现各腺病毒治疗组的CD4+和CD8+细胞水平以及NK、CTL细胞的杀伤活性均高于对照组,尤以携带IL-12基因者明显(P＜0.001).结论:以增生型腺病毒为载体携带IL-12基因可大量杀伤肿瘤细胞并与增生型腺病毒协同发挥抗肿瘤活性.

Reference

[1]Hai-Qiang Guo,Peng Guan,Hai-Long Shi,etc.Prospective cohort study of comprehensive prevention to gastric cancer[J].2003,(3).
[2]Xue-Ying Shi,Feng-Zhi Zhao,Xin Dai,etc.Effect of jianpiyiwei capsule on gastric precancerous lesions in rats[J].2002,(4).
[3]杨家和,钱其军,吴孟超,等.白介素12:重要的免疫调节因子[J].1999,(1).
[4]魏道严,戴冰冰,王中和,等.腺病毒载体介导mIL-12基因治疗联合放射治疗小鼠肝癌的研究[J].2001,(4).
[5]Yong-Bin Ding,Guo-Yu Chen,Jian-Guo Xia,etc.Correlation of tumor-positive ratio and number of perigastric lymph nodes with prognosis of patients with surgically-removed gastric carcinoma[J].2004,(2).
[6]Ji ZHANG,Xiang-qian Su,Xiao-jiang Wu,etc.Effect of body mass index on adenocarcinoma of gastric cardia[J].2003,(12).
[7]Guo HaG Wu,Yan Wei Zhang,Zhao Han Wu.Modulation of postoperative immune and inflammatory response by immune-enhancing enteral diet in gastrointestinal cancer patients[J].2001,(3).
[8]Yong Yu,Yi-Chu Zhang,Wen-Zhu Zhang,etc.Ets1 as a marker of malignant potential in gastric carcinoma[J].2003,(10).
[9]钱其军,吴孟超,刘新垣.肿瘤的基因-病毒治疗的研究热点[J].2001,(2).
[10]薛绪潮,方国恩,张琪,等.增殖型腺病毒载体介导mIL-12基因对胃癌细胞的杀伤作用[J].2004,(1).
[11]B D, Car,V M, Eng,J M, Lipman,etc.The toxicology of interleukin-12: a review.[J].1900,27(1).
[12]O, Wildner,R M, Blaese,J C, Morris.Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase.[J].1999,59.
[13]E, Galanis,R, Vile,S J, Russell.Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors.[J].2001,38(3).
[14]J R, Bischoff,D H, Kirn,A, Williams,etc.An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.[J].1996,274.
[15]R, Zhang,L J, DeGroot.Genetic immunotherapy of established tumours with adenoviral vectors transducing murine interleukin-12 (mIL12) subunits in a rat medullary thyroid carcinoma model.[J].2000,52(6).
[16]Smyth MJ,Taniguchi M,Street SE.The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent.[J].2000,165(5).
[17]D C, Yu,G T, Sakamoto,D R, Henderson.Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy.[J].1999,59.
[18]D, Kirn.Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials.[J].2001,1(3).
[19]Kurihara T,Brough DE,Kovesdi I,etc.Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.[J].2000,106(6).
[20]Hu J,Shimura S,Lee HM,etc.Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model.[J].1999,6(3).
[21]W, Su,T, Ito,T, Oyama,etc.The direct effect of IL-12 on tumor cells: IL-12 acts directly on tumor cells to activate NF-kappaB and enhance IFN-gamma-mediated STAT1 phosphorylation.[J].2001,280.
[22]Steinwaerder DS,Carlson CA,Li ZY,etc.Tumor-specific gene expression in hepatic metastases by a replication-activated adenovirus vector.[J].2001,7(2).
[23]Vokes E,Kuhn J,Nemunaitis J,etc.Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer.[J].2001,19(2).
[24]Ortega A.,Graham F.,Enjuanes L.,etc.Tropism of Human Adenovirus Type 5-Based Vectors in Swine and Their Ability to Protect Against Transmissible Gastroenteritis Coronavirus[J].1996,70(6).
[25]Mazzolini G,Narvaiza I,Perez-Diez A,etc.Genetic heterogeneity in the toxicity to systemic adenoviral gene transfer of interleukin-12.[J].2001,8(4).
[26]Heise CC,Williams A,Olesch J,etc.Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects.[J].1999,6(6).
[27]G A, Prince,D D, Porter,A B, Jenson,etc.Pathogenesis of adenovirus type 5 pneumonia in cotton rats (Sigmodon hispidus).[J].1993,67.
[28]Zhang R,DeGroot LJ,Hashizume K,etc.Effective gene therapy for medullary thyroid carcinoma using recombinant adenovirus inducing tumor-specific expression of interleukin-12.[J].2002,9(1).